BluefitMD

The short answer is: it’s hard to name any telehealth service that can still openly and broadly offer compounded GLP-1s for weight loss after the FDA crackdown, because the FDA has sent warning letters to 30 telehealth companies over misleading or illegal marketing of compounded GLP-1s, and the market has shifted away from mass-market compounded semaglutide/tirzepatide offers.[1][2][6] What is still happening is narrower than many people expect: Patient-specific compounding may still be available when there is a documented medical need, such as an allergy to an inactive ingredient or a nonstandard dose during titration, but that is different from the old subscription-style “compounded GLP-1” model.[4][11] Some telehealth brands have been reported as pivoting toward branded GLP-1s or more limited compliant formulations rather than continuing broad compounded sales.[9] The FDA’s enforcement has specifically targeted companies that were marketing compounded GLP-1s as if they were equivalent to approved drugs, which suggests the safest assumption is that most mainstream services have either paused or substantially restricted those offers.[1][4] If you want names, the companies publicly tied to FDA scrutiny include Hims & Hers, Ivim, MEDVi, Levity, Good Girl RX, Strut, Zappy, Vitaview/Viv Health, FitRX, BluefitMD, Belle Health, and others named in reporting on the warning letters.[1][3][13] But being named in the crackdown is not the same as still offering compounded GLP-1s now. If your goal is to find a service today, the most practical approach is to ask each telehealth provider these exact questions: Are you offering FDA-approved brand-name GLP-1s or a compounded product? If compounded, is it for a patient-specific medical need only? Which licensed compounding pharmacy fills it? Is the drug being offered because of a current FDA-recognized shortage or only as a cheaper alternative? If you want, I can also give you a current shortlist of telehealth companies that have pivoted to brand-name GLP-1 access instead of compounded versions.

Mentioned in position 10 of 11

The main answer is: it depends on whether you mean “still legally offer compounded GLP-1s” or “still market them anyway.” Based on the results you shared, the telehealth services most clearly identified as still offering compounded GLP-1s are Noom and some smaller operators that received FDA warning letters, while larger brands like Ro and Hims & Hers have largely pivoted toward branded/authorized supply partnerships instead of compounded versions.[5][9][2] What the results support most clearly: Noom is specifically described as still selling compounded GLP-1 versions under the FDA’s personalized-dosing exception, with a separate branded supply arrangement through LillyDirect.[5][9] Smaller telehealth brands named in FDA warning letters were still marketing compounded GLP-1s as of the crackdown, including Bliv, Belle, FitRx, BluefitMD, Viv Health/VIV RX, GoodGirlRX, MEDVi, Levity, Ivim, Strut, Peaks, Refills Health, and others listed in the reports.[2][7][8] Hims & Hers was specifically singled out by the FDA and later referred for investigation, but the available results suggest it was being pushed away from compounded GLP-1s rather than clearly continuing them in a straightforward way.[3][2] Ro and WeightWatchers are described as having pivoted toward authorized branded GLP-1 access and broader obesity-care offerings rather than compounded supply.[5][9] A practical way to read this in 2026: If you want compounded semaglutide/tirzepatide, the safest interpretation is that many telehealth brands no longer offer them openly, and the ones that do are the ones attracting FDA scrutiny.[1][4][6] If you want a service that still offers GLP-1 treatment online, the more stable options now appear to be branded/authorized channels like Noom’s LillyDirect-linked offering, Ro, and some other telehealth platforms that have switched away from compounded products.[5][9] If you want, I can turn this into a brand-by-brand status list of the major telehealth companies and note which ones appear to still have compounded GLP-1 access versus which have moved to branded alternatives.

Mentioned in position 7 of 17

A few telehealth brands were still reported in 2026 as offering compounded GLP-1s despite the FDA crackdown, but the landscape is changing fast and many providers have shifted to branded drugs or stopped compounded GLP-1 sales altogether.[2][5][7][12] The clearest names mentioned in the search results as still involved are: Hims & Hers — Reuters and Yahoo Finance both describe Hims as continuing to be scrutinized while still connected to compounded GLP-1 offerings, even after moving into branded-drug partnerships.[2][7][12] Ro — Yahoo Finance reports Ro continued to provide compounded GLP-1 versions, including semaglutide, despite recent partnerships with Lilly.[7] Noom — Yahoo Finance also says Noom continued offering compounded GLP-1 versions.[7] MD Exam — a Reddit comment in the results says compounded GLP-1 access was still available through MD Exam, but this is not as authoritative as FDA or Reuters reporting.[11] Good Life — also mentioned only in that Reddit discussion as a possible still-active option.[11] The FDA’s enforcement focus has been on false or misleading marketing around compounded GLP-1s, especially claims that these products are equivalent to approved drugs or that telehealth companies themselves are the manufacturers.[1][6][8] The FDA also issued warning letters to many telehealth firms, including names such as Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, GoodGirlRx, and others listed in the reporting.[3][8][11] If you want, I can turn this into a current “still offering vs. stopped” list by brand and flag which ones appear to have switched to branded Wegovy/Zepbound instead of compounded semaglutide/tirzepatide.

Mentioned in position 9 of 12